Core Insights - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of Cyprium's Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million, marking a significant corporate transaction for both entities [1][2] Financial Impact - Fortress expects to receive over $100 million from the PRV sale, which will enhance its financial flexibility for business development and advancing its portfolio [2] - Cyprium is eligible for tiered royalties on net sales of ZYCUBO® and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics [3] Product Development and Approvals - Fortress' portfolio has achieved three FDA approvals in the last 15 months for products Emrosi™, UNLOXCYT™, and ZYCUBO® [2] - ZYCUBO® was approved by the FDA on January 12, 2026, for the treatment of Menkes disease in pediatric patients [4] Corporate Structure and Strategy - Cyprium is a majority-owned subsidiary of Fortress, focusing on novel therapies for Menkes disease and related disorders [4] - Fortress operates with a model aimed at acquiring and advancing biopharmaceutical assets to enhance long-term shareholder value through various revenue streams [5]

Core Viewpoint - Nutriband has selected a commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit it to the FDA for approval [1][3] Group 1: Product Development - Nutriband's lead product utilizes AVERSA™ abuse deterrent technology, which aims to prevent the abuse and misuse of transdermal fentanyl [2][7] - The product has the potential to achieve peak annual US sales between $80 million to $200 million, with plans for development in major medical markets worldwide [3][9] Group 2: Branding and Regulatory Support - The company has partnered with Brand Institute, Inc. to develop the brand name and visual identity for the product, leveraging their expertise in pharmaceutical branding [2][5] - Drug Safety Institute, a subsidiary of Brand Institute, will provide regulatory services and support, staffed by former officials from major health agencies [6][11] Group 3: Intellectual Property - Nutriband's AVERSA™ technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries [7][8]

Core Insights - Off The Hook YS Inc. achieved record revenue of $119.9 million in 2025, representing a 21.1% increase year-over-year [1][6] - The company sold a record 426 boats in 2025, up 33% from the previous year [1][3] - Revenue guidance for 2026 has been increased to between $150 million and $155 million [5] Financial Performance - Revenue for 2025 increased to $119.9 million from $99.0 million in 2024, driven by higher floorplan limits and increased sales [6][7] - Pre-owned boat sales rose by 20% to $101.7 million, while new boat sales increased by 32% to $14.5 million [6][9] - Gross profit for 2025 was $11.5 million, a 30.6% increase from $8.8 million in 2024 [7][10] Operational Highlights - The average monthly utilization of the company's floorplan financing increased by 78% to $23.4 million in 2025 [6] - The company expanded its national broker network and infrastructure, positioning itself for continued double-digit growth [2][3] - Operating expenses for 2025 were $10.7 million, up from $5.8 million in 2024, primarily due to increased marketing and public company-related costs [11][12] Market Position - Off The Hook Yachts is the largest buyer and seller of used boats in the U.S. and is focused on the pre-owned segment where long-term demand remains strong [1][3] - The company believes it is well-positioned to accelerate growth in 2026, supported by expanded floorplan capacity and increased broker productivity [3][17] Liquidity and Capital Structure - The company completed its IPO in November 2025, raising approximately $13.4 million in net proceeds, which strengthened its balance sheet [7][14] - As of December 31, 2025, cash increased to $12.4 million from $2.93 million on September 30, 2025 [13][14] - Working capital improved to $9.4 million, compared to negative $0.4 million in the previous year [14]

Core Insights - AEON Biopharma announced positive initial comparative analytical results for ABP-450, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX [1][3] - The company reported constructive feedback from the FDA following a BPD Type 2a meeting, providing a clear framework for advancing the comparative analytical plan for the ABP-450 biosimilar program [1][2] - AEON strengthened its balance sheet through a $6 million PIPE financing and a note exchange, reducing outstanding debt by more than 90% [1][3] Financial Performance - As of December 31, 2025, AEON reported cash and cash equivalents of $3.0 million, which does not include $4.2 million from the second closing of the PIPE financing in January 2026 [5] - The company incurred a net loss of $39.2 million for the year ended December 31, 2025, compared to a net income of $42.0 million in 2024 [17] Corporate Developments - John Bencich was appointed as Chief Financial Officer, bringing over 25 years of leadership experience in corporate strategy and capital markets [4][10] - AEON plans to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program for ABP-450 [3] Market Context - The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a significant opportunity for biosimilar entry [7] - ABP-450 is manufactured by Daewoong Pharmaceutical in a facility authorized by the FDA, Health Canada, and the European Medicines Agency [7]

Core Insights - ARKO Petroleum Corp. reported financial results for Q4 and the full year 2025, highlighting a positive trajectory following its IPO in February 2026, which strengthened its balance sheet and positioned the company for growth opportunities in a fragmented market [5][6]. Financial Performance - Net income for Q4 2025 increased to $8.1 million from $7.5 million in Q4 2024, while full-year net income decreased to $32.7 million from $40.2 million [6]. - Adjusted EBITDA for Q4 2025 rose to $36.9 million compared to $35.4 million in Q4 2024, and for the full year, it increased to $143.5 million from $139.2 million [6]. - Net cash provided by operating activities for Q4 2025 was $16.4 million, down from $35.1 million in Q4 2024, and for the year, it decreased to $79.6 million from $106.8 million [6]. - Discretionary Cash Flow for Q4 2025 was $21.1 million, up from $20.5 million in Q4 2024, while for the year, it increased to $88.9 million from $79.9 million [6]. IPO and Debt Management - The company completed its IPO on February 13, 2026, issuing 11,111,111 shares at $18.00 per share, and subsequently sold an additional 1,459,112 shares, representing 26.4% of economic interests [6]. - Approximately $206.7 million of net proceeds from the IPO was used to reduce debt, resulting in a net debt of $319.9 million after adjustments [6]. Segment Highlights Wholesale Segment - Fuel gallons sold at fuel supply locations increased to 211,406 thousand in Q4 2025 from 201,317 thousand in Q4 2024, and for the year, it rose to 836,232 thousand from 794,796 thousand [7]. - Fuel contribution from fuel supply locations increased to $13.7 million in Q4 2025 from $12.0 million in Q4 2024, and for the year, it rose to $52.5 million from $47.9 million [7]. - Fuel margin per gallon at fuel supply locations increased to 6.5 cents in Q4 2025 from 6.0 cents in Q4 2024 [7]. Fleet Fueling Segment - Fuel gallons sold at proprietary cardlock locations decreased to 31,420 thousand in Q4 2025 from 32,888 thousand in Q4 2024, while for the year, it decreased to 129,459 thousand from 136,104 thousand [16]. - Fuel contribution from proprietary cardlock locations was $15.4 million in Q4 2025, down from $15.8 million in Q4 2024, but increased to $63.4 million for the year from $62.6 million [19]. GPMP Segment - Fuel gallons sold to related party locations decreased to 204,000 thousand in Q4 2025 from 246,320 thousand in Q4 2024, and for the year, it decreased to 864,800 thousand from 1,023,480 thousand [20]. - Fuel contribution from related party locations decreased to $10.2 million in Q4 2025 from $12.3 million in Q4 2024, and for the year, it decreased to $43.2 million from $51.2 million [20]. Liquidity and Capital Expenditures - As of December 31, 2025, total liquidity was approximately $434.3 million, consisting of $15.6 million in cash and $418.7 million available under the credit line [25]. - Maintenance capital expenditures were $2.8 million for Q4 2025 and $6.9 million for the full year, while growth capital expenditures were $6.1 million for Q4 and $20.6 million for the year [25]. Dividend Declaration - The Board declared a quarterly dividend of $0.26 per share to be paid on April 21, 2026, representing an expected annual dividend rate of $2.00 per share, which corresponds to a yield of 10% to 11% at a share price of $18.50 to $19.50 [6][26].

Core Insights - RenovoRx generated $1.1 million in revenue from RenovoCath in its first full year of commercialization, indicating strong initial adoption by physicians and demand in active cancer centers [2][3][15] - The company has established a solid commercial infrastructure and plans to scale operations in 2026, focusing on high-volume cancer centers [2][10] - The ongoing Phase III TIGeR-PaC trial is on track for full enrollment by mid-2026, with final data expected in 2027 [1][7][8] Financial Performance - For the year ended December 31, 2025, RenovoRx reported revenue of $1.1 million, a significant increase from $43,000 in 2024 [15][25] - The net loss for 2025 was approximately $11.2 million, compared to $8.8 million in the previous year [19][25] - Cash and cash equivalents were approximately $7.0 million as of December 31, 2025, and increased to $13 million following a private placement in March 2026 [16][14] Commercialization and Market Strategy - As of early 2026, 12 cancer centers are actively using RenovoCath, with an additional 21 centers evaluating or preparing for activation, tripling the near-term pipeline compared to early 2025 [2][5] - The company estimates a total addressable market (TAM) of approximately $400 million for RenovoCath as a stand-alone device, with potential for multi-billion-dollar expansion into additional solid tumor indications [6][29] - The company is observing repeat ordering patterns and increased procedural utilization, reinforcing confidence in physician satisfaction and the potential for recurring revenue [5][4] Clinical Development - The TIGeR-PaC trial is evaluating intra-arterial delivery of gemcitabine via RenovoCath for locally advanced pancreatic cancer, with 104 patients randomized as of March 24, 2026 [7][8] - The trial has reached a key milestone with the completion of a second interim analysis, and the independent Data Monitoring Committee recommended continuing the study without modification [8][9] - The company aims to transition 17 cancer centers involved in the TIGeR-PaC trial to commercial customers for RenovoCath in the second half of 2026 [2][7] Leadership and Advisory Board - In February 2026, RenovoRx strengthened its executive leadership team with the appointment of Mark Voll as Chief Financial Officer, bringing over 30 years of financial leadership experience [11] - The company established the RenovoCath Medical Advisory Board to provide strategic clinical guidance, comprising leading interventional oncology experts [12]

Core Insights - Invivyd, Inc. presented advancements in monoclonal antibody (mAb) therapies at the World Vaccine Congress, emphasizing the need for treatments that can adapt to rapidly evolving viral threats [1][8] - The company aims to address the limitations of current vaccinology by developing mAb treatments for vulnerable populations, focusing on scalability, access, and economic factors [2] Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [5] - The company utilizes a proprietary integrated technology platform to develop and adapt high-quality antibodies [5] Event Details - The World Vaccine Congress is recognized as the largest global meeting for vaccine discussions, featuring a wide range of topics and speakers from various sectors [3] - The event facilitates collaboration among scientists, government officials, and manufacturers to drive progress in vaccine development [3]

Core Viewpoint - TFI International Inc. will release its financial results for Q1 2026 on April 27, 2026, after market close, and will host a webcast to discuss these results [1]. Group 1: Company Overview - TFI International Inc. is a leader in the North American transportation and logistics industry, operating in the United States, Canada, and Mexico through its subsidiaries [2]. - The company focuses on creating shareholder value by identifying strategic acquisitions and managing a growing network of wholly-owned operating subsidiaries [2]. - TFI International provides financial and operational resources to its subsidiaries, enhancing their business efficiency [2]. Group 2: Webcast Details - The webcast will feature Alain Bédard, Chairman, President and CEO, and David Saperstein, Chief Financial Officer, discussing the financial results [1][3]. - The live webcast is scheduled for April 27, 2026, at 5:00 PM Eastern Time, and will be available for replay on the company's website [3].

Core Insights - ARRAY Technologies has announced the opening of a new headquarters for APA Solar, enhancing its capabilities in solar racking and foundation solutions [1][5] - The new 30,000 square foot facility aims to foster collaboration and innovation by integrating customer-facing roles with engineering and manufacturing teams [2][5] - The expanded campus will house the Foundations Center of Excellence, focusing on foundation innovations for challenging soil conditions and enhancing interoperability with ARRAY's tracker solutions [3][5] Company Developments - The new headquarters will include a research, testing, and training center, featuring a 5-acre solar site dedicated to new product development [4] - The integration of APA Solar into ARRAY has exceeded expectations, with the new facility expected to accelerate growth in the utility-scale solar market [5] - APA Solar remains committed to U.S. domestic manufacturing and has maintained its primary operations in Ohio since its inception in 2008 [5] Strategic Implications - The new headquarters and Center of Excellence are seen as critical for enhancing collaboration across engineering, manufacturing, and commercial sectors, thereby shortening the development cycle [5] - This investment reflects ARRAY's confidence in the potential of APA Solar to contribute to the company's growth and innovation strategy [5] - The facility is positioned to support ARRAY's strategic imperative for innovation in the solar energy sector [5]

Core Insights - zSpace, Inc. reported its financial results for Q4 and the full year 2025, highlighting a strategic focus on software and services, which now comprise 53% of revenue, up from 43% a year ago, contributing to a gross margin expansion of over 840 basis points [2][4][6]. Financial Performance - Q4 2025 revenue was $4.8 million, down from $8.5 million in Q4 2024, while full year 2025 revenue totaled $27.9 million compared to $38.1 million in 2024, primarily due to a freeze in orders and shipments during the U.S. Federal Government shutdown [4][6]. - Gross margin for Q4 2025 increased to 49% from 41% in Q4 2024, and for the full year, it rose to 48% from 41% in 2024, driven by improved hardware cost profiles and more company-owned software content [4][7]. - The net loss for Q4 2025 was ($7.3) million compared to ($3.6) million in Q4 2024, and the full year net loss was ($25.4) million versus ($20.8) million in 2024 [4][10]. Business Highlights - zSpace launched the zStylus One, an AI-enabled stylus, on November 18, 2025, enhancing AR deployment across its product lines [4]. - A strategic restructuring initiative completed on December 11, 2025, reduced operating expenses by over 30% [4]. - zSpace secured a $3 million strategic investment from Planet One Education on January 29, 2026, aimed at enhancing liquidity and supporting international collaboration [4]. - The company expanded its presence in Italy with new school deployments and training initiatives, gaining national visibility [4]. - On March 17, 2026, zSpace announced a $4.3 million senior secured convertible note to enhance working capital and support corporate purposes [4]. Key Metrics - Annualized Contract Value (ACV) of renewable software as of December 31, 2025, was $9.9 million, a 12% decrease year-over-year [7]. - Net Dollar Revenue Retention (NDRR) for customers with over $50,000 of ACV was 71% as of December 31, 2025 [8]. - Bookings in Q4 2025 were $3.4 million, down 21% year-over-year, while full year bookings were $26.1 million, down 34% year-over-year [8]. Balance Sheet - As of December 31, 2025, zSpace had approximately $1.0 million in cash and cash equivalents, down from $4.9 million a year earlier [11]. - Total liabilities increased to $30.1 million from $28.2 million in 2024, with stockholders' deficit growing to ($22.5) million from ($14.7) million [11][23].